Inhibition of Myc effectively targets KRAS mutation-positive lung cancer expressing high levels of Myc.
Fukazawa
Takuya
T
Department of General Surgery, Kawasaki Medical School, Okayama, Japan. FukazawaT@aol.com
Maeda
Yutaka
Y
Matsuoka
Junji
J
Yamatsuji
Tomoki
T
Shigemitsu
Kaoru
K
Morita
Ichiro
I
Faiola
Francesco
F
Durbin
Mary L
ML
Soucek
Laura
L
Naomoto
Yoshio
Y
D000230:Adenocarcinoma / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D000818:Animals; D045744:Cell Line, Tumor; D005260:Female; D011905:Genes, ras; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D009154:Mutation; D016271:Proto-Oncogene Proteins c-myc / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000235:genetics; D014183:Transplantation, Heterologous
C489427:MYC protein, human; D016271:Proto-Oncogene Proteins c-myc